Bio-Techne Announces Key Leadership Changes for Future Growth

Bio-Techne Corporation, a prominent player in the life sciences industry, has made significant adjustments to its leadership team as it prepares for the next stage of growth. Effective March 1, 2026, Dr. Matt McManus will transition from his role as President of the Diagnostics and Spatial Biology Segment, a move announced on February 11, 2026. In his place, Steve Crouse, the Senior Vice President of Bio-Techne's Analytical Solutions Division, will take on the role of President.

Dr. McManus has been at the forefront of Bio-Techne's operations, playing a pivotal role in refining organizational strategies, which included the strategic divestiture of the Exosome business. Under his leadership, the company has witnessed substantial advancements in the biotechnological sphere, further solidifying its commitment to innovation in diagnostics and research tools. His departure signals a new chapter for the company as leadership transitions toward new opportunities.

Steve Crouse, who is set to take over the Diagnostic and Spatial Biology Segment, brings with him a wealth of experience in the life sciences sector, boasting over two decades of leadership roles across various companies. Serving as a Senior Vice President at Bio-Techne, he has been instrumental in overseeing the portfolio of protein analysis tools and immunoassays. His achievements include the successful launch of innovative platforms and driving impressive growth metrics throughout his tenure.

Before joining Bio-Techne, Crouse served as the General Manager for Thermo Fisher Scientific's Protein Detection and Quantification business unit, which has equipped him with the necessary skills and insights to excel in his new role.

Kim Kelderman, President and CEO of Bio-Techne, expressed gratitude for Dr. McManus’s contributions, acknowledging his impactful leadership and the legacy he leaves behind in fostering a culture of innovation and excellence within the organization. Kelderman emphasized Crouse’s visionary leadership as a crucial factor for the future direction of the company, highlighting his extensive experience in pioneering life science solutions.

As Crouse steps into his new position, he will collaborate closely with Will Geist, who serves as President of Bio-Techne's Protein Sciences Segment. This partnership aims to drive further growth and innovation within Bio-Techne, reinforcing its commitment to delivering cutting-edge tools and bioactive reagents to the research and clinical diagnostic sectors.

Bio-Techne Corporation, traded on NASDAQ as TECH, has established itself as a leader in the life sciences space, offering innovative solutions to assist scientific endeavors in understanding complex biological processes and disease progression. In the fiscal year 2025, Bio-Techne achieved over $1.2 billion in net sales, highlighting its robust market position and commitment to advancing healthcare through scientific innovation.

With a vast portfolio encompassing hundreds of thousands of products and a workforce of approximately 3,100 employees worldwide, Bio-Techne continues to expand its reach and impact in the life sciences arena. The upcoming leadership changes are viewed as a strategic move to enhance the company's competitive edge and ensure sustained growth in a rapidly evolving industry.

For those interested in learning more about Bio-Techne and its extensive range of products, please visit www.bio-techne.com. Follow the company on LinkedIn, X, or YouTube for the latest updates and innovations.

In conclusion, the leadership transition marks a significant shift within Bio-Techne, as it seeks to leverage the strengths of its new President to navigate future challenges and opportunities in the life sciences market.